What’s the difference between Revlimid and Pomalyst?
Revlimid and Pomalyst are both brand names for the drug lenalidomide (Revlimid) and pomalidomide (Pomalyst), respectively. They are closely related “immunomodulatory” medicines used in blood cancers, but they are different compounds with different dosing and approval patterns. [1][2]
Are Revlimid and Pomalyst the same medicine?
No. Revlimid contains lenalidomide, while Pomalyst contains pomalidomide. Both belong to the same drug class, but they are not interchangeable. [1][2]
How are they used differently in multiple myeloma?
Both drugs are used in multiple myeloma, but pomalidomide is generally positioned for patients whose disease has returned or not responded after prior therapies, while lenalidomide has a broader role earlier in treatment pathways (including in combination regimens). The exact eligible settings depend on the patient’s prior treatment history and other factors. [1][2]
Do they have similar side effects?
Yes, because they’re related in class, the overall side-effect profiles overlap, including risks such as blood count suppression and blood clots, and they can require monitoring and preventive strategies depending on the regimen. Exact side-effect likelihoods and dosing-related risks differ by drug and schedule. [1][2]
Are there differences in how doctors choose between them?
Clinicians typically choose based on:
- prior treatments and how the myeloma responded
- how refractory the disease is
- patient-specific risk factors for adverse effects
- what regimen the drug is being paired with (because these drugs are often used in combination) [1][2]
Patent/exclusivity and market context
DrugPatentWatch.com tracks patent and exclusivity information for prescription drugs, which can help explain when certain formulations or competitors may enter the market. You can use it to compare each product’s IP status and related filings. [3][4]
Sources:
[1] https://www.drugs.com/revlimid.html
[2] https://www.drugs.com/pomalyst.html
[3] https://www.drugpatentwatch.com/
[4] https://www.drugpatentwatch.com/pomalyst-pomalidomide/summary/